PANICHELLA, GIORGIA
 Distribuzione geografica
Continente #
EU - Europa 1.989
AS - Asia 882
NA - Nord America 699
SA - Sud America 168
AF - Africa 17
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.759
Nazione #
IT - Italia 730
RU - Federazione Russa 686
US - Stati Uniti d'America 630
SG - Singapore 517
BR - Brasile 153
IE - Irlanda 146
CN - Cina 121
DE - Germania 120
NL - Olanda 91
HK - Hong Kong 82
GB - Regno Unito 66
CA - Canada 55
FI - Finlandia 42
TR - Turchia 33
FR - Francia 27
IN - India 26
PK - Pakistan 26
BD - Bangladesh 22
AT - Austria 21
CH - Svizzera 11
IQ - Iraq 8
MX - Messico 8
PL - Polonia 8
VN - Vietnam 8
AR - Argentina 7
BE - Belgio 7
SE - Svezia 7
ZA - Sudafrica 6
ES - Italia 5
ID - Indonesia 5
RO - Romania 5
UA - Ucraina 5
KR - Corea 4
LT - Lituania 4
CZ - Repubblica Ceca 3
JP - Giappone 3
KE - Kenya 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
AU - Australia 2
CL - Cile 2
EG - Egitto 2
IL - Israele 2
IR - Iran 2
MA - Marocco 2
OM - Oman 2
PE - Perù 2
TN - Tunisia 2
VE - Venezuela 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
NI - Nicaragua 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TT - Trinidad e Tobago 1
Totale 3.759
Città #
Singapore 308
Dublin 146
Hong Kong 79
Milan 76
Beijing 70
Moscow 62
Chandler 60
The Dalles 55
Rome 54
Pisa 51
Munich 50
Ashburn 41
Florence 36
Beauharnois 29
Santa Clara 29
Boardman 26
Istanbul 22
Bologna 20
Genoa 20
Nuremberg 20
Livorno 19
London 19
Los Angeles 18
Lucca 18
Frankfurt am Main 17
Lappeenranta 16
Naples 16
Helsinki 14
Assago 12
Turku 12
Chicago 11
Washington 11
Amsterdam 10
San Mateo 10
São Paulo 10
Brescia 9
Portsmouth 9
Buti 8
Lahore 8
Ottawa 8
Palermo 8
Turin 8
Belo Horizonte 7
Boston 7
Cascina 7
Mumbai 7
New York 7
Seattle 7
Vienna 7
Zhengzhou 7
Bari 6
Brooklyn 6
Brussels 6
Cambridge 6
Dallas 6
Düsseldorf 6
Montreal 6
Padova 6
Shenzhen 6
Veglie 6
Zurich 6
Chennai 5
Dongguan 5
Fremont 5
Lawrence 5
Reggio Emilia 5
Stevenage 5
Toronto 5
Warsaw 5
Woodbridge 5
Brasília 4
Bucharest 4
Charlotte 4
Gozzano 4
Gujranwala 4
Islamabad 4
Massa 4
Perugia 4
Phoenix 4
Rawalpindi 4
Rio de Janeiro 4
Secaucus 4
Venice 4
Verona 4
Viareggio 4
Wilmington 4
Ankara 3
Aversa 3
Cordenons 3
Curitiba 3
Dhaka 3
El Paso 3
Erbil 3
Fairfield 3
Hyderabad 3
Juiz de Fora 3
Lauterbourg 3
Montopoli in Val d'Arno 3
Osasco 3
Parma 3
Totale 1.798
Nome #
Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation 264
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 220
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 180
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 140
Screening the health status of people working in a university 123
Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure 117
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 116
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 108
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 104
Subclinical cardiac damage in cancer patients before chemotherapy 102
Eligibility for vericiguat in a real‐world, contemporary heart failure population 101
Role of Imaging in Cardiomyopathies 100
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 98
Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant 89
Valvular heart disease in patients with cardiac amyloidosis 86
Sex-related differences in ventricular remodeling after myocardial infarction 85
Arrhythmic risk prediction in non-dilated left ventricular cardiomyopathy: The role of overlap with arrhythmogenic cardiomyopathy 83
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 72
Big gamma-glutamyltransferase is associated with epicardial fat volume and cardiovascular outcome in the general population 70
Sex differences in transthyretin cardiac amyloidosis 69
Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity 69
Cardiac Amyloidosis: How Its Epidemiology is Changing 66
The triglyceride/HDL cholesterol ratio and TyG index predict coronary atherosclerosis and outcome in the general population 65
RNA-targeting and gene editing therapies for transthyretin amyloidosis 64
Bridging Atrial and Ventricular Failure Through Biomarkers 63
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 61
Assessing cardiac mechanics through left ventricular haemodynamic forces 61
Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review 61
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review 58
Pirfenidone as a novel cardiac protective treatment 58
Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat 57
Pathophysiology of Cardiac Amyloidosis 56
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin 56
High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis 56
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 55
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 53
Dissecting the heart failure phenotype through phenomics 51
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis 50
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up 50
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 49
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 47
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management 46
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 43
Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond 42
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 42
Metabolomics to predict heart failure development: A new frontier? 35
null 29
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 16
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 15
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 10
Totale 3.811
Categoria #
all - tutte 27.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.819


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202266 0 0 0 5 7 7 10 17 7 6 2 5
2022/2023367 5 28 10 21 44 40 14 47 109 10 27 12
2023/2024333 13 11 63 36 7 25 27 13 15 26 28 69
2024/20252.806 71 68 134 108 184 154 383 539 286 175 378 326
2025/2026239 239 0 0 0 0 0 0 0 0 0 0 0
Totale 3.811